Compare Ishares Msci Brazil ETF (EWZ) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs 10X Genomics Inc — how do they compare? Ishares Msci Brazil ETF trades at $43.1 (market cap $11.30B), while 10X Genomics Inc trades at $79.1 (market cap $10.07B). The key difference: Ishares Msci Brazil ETF and 10X Genomics Inc are close in size by market cap, and Ishares Msci Brazil ETF is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and 10X Genomics Inc for 92 Days on average.
| EWZ | TXG | |
|---|---|---|
Market Cap | $11.30B | $10.07B |
Volume | 44,036,597 | 5,657,286 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.00 | $97.74 |
52-Week Low | $28.79 | $11.48 |
Typical Hold Time | 50 Days | 92 Days |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $42.37, down 1.47% today. The technical outlook is mixed with moving averages signaling bullish momentum but oscillators showing bearish pressure, including overbought RSI readings. Recent news highlights significant investor focus on Brazil's upcoming October election, with unusual options activity and institutional positioning suggesting anticipation of market-moving outcomes. The ETF serves as a key diversifier for U.S. investors seeking exposure to Brazilian equities and commodities.
The outlook for EWZ is heavily tied to Brazilian political and economic developments, particularly the election outcome. While technical indicators show conflicting signals, the substantial options volume and institutional interest indicate heightened expectations for volatility. Key risks include election uncertainty and U.S.-Brazil trade tensions, but potential rate cuts and commodity exposure offer upside for diversified portfolios.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
